Learn More
7567 Background: Third-line treatment option for advanced NSCLC patients is very limited with a lack of effective drugs and specific trials targeting this patient population. V+B combination was(More)
Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free(More)
  • 1